scholarly journals The estimation of competitive positions of non-steroid anti-inflammatory drugs on pharmaceutical market of Ukraine

2018 ◽  
Vol 65 (1) ◽  
pp. 10-14
Author(s):  
A. A. Kotvitska ◽  
V. H. Kostiuk
Keyword(s):  
Market Share ◽  
Pharmaceutical Manufacturing ◽  
Competitive Strategies ◽  
Competitive Position ◽  
Manufacturing Enterprises ◽  
Inflammatory Drugs ◽  
Anti Inflammatory ◽  
Trade Names ◽  
Level Calculation ◽  
Selective Nsaid

Abstract The aim of our analysis is the estimation of non-steroid anti-inflammatory drugs (NSAID) competitiveness level, calculation of capacity, share and saturation of studied segment of market that allow to improve the competitive strategies of pharmaceutical manufacturing enterprises. MATERIALS AND METHODS: According to the results of content-analysis of foreign and native economic literature, we elaborated the methodology of estimation of NSAID competitive positions that consists of six main stages. The offered model of estimation of competitiveness of the studied group of medicines is based on the construction of competition map of medicines on the example of non-selective NSAID as the largest group by the number of presented trade names (TN) using the calculation of market share of medicines for 2015-2016 and dynamics of its growth. RESULTS: The results of NSAID TN distribution in groups according to the market share volume testify that only 8 TN of medicines among 74 are the leaders of market and 10 TN are characterized with strong competitive position. At the same time 51 NSAID TN are outsiders and 5 TN have weak competitive position. The results of NSAID TN distribution in groups according to the change of their competitive position allow state that 16 TN among 74 have fast worsening competitive position, 43 TN belong to the group with worsening competitive position and only 5 TN has competitive position, characterized by fast improvement. CONCLUSION: The analysis of position, occupied by NSAID TN in matrix, demonstrated that 8 TM of medicines are the leaders of the market. At the same time 51 medicines TN are outsiders. The results of research demonstrated that 59 NSAID TN are characterized with worsening and fast worsening competitive positions.

scholarly journals CONTENT-ANALYSIS OF THE PHARMACEUTICAL MARKET OF NONSTEROIDAL ANTI-INFLAMMATORY DRUGS IN GROUPS OF ACETIC ACID DERIVATIVES IN THE KYRGYZ REPUBLIC

2020 ◽  
Vol 22 (1) ◽  
pp. 74-81
Author(s):  
Dinara Ermekova ◽  
◽  
Isabek Ismailov ◽  
Keyword(s):  
Acetic Acid ◽  
Medical Engineering ◽  
Pharmaceutical Market ◽  
High Price ◽  
Kyrgyz Republic ◽  
Foreign Countries ◽  
Price Range ◽  
Inflammatory Drugs ◽  
Anti Inflammatory ◽  
Trade Names

Objective: To segment the pharmaceutical market of non-steroidal anti-inflammatory drugs (NSAIDs) of the derivatives groups of acetic acid in the Kyrgyz Republic. Methods: The database of the State Registry of Medicines registered and approved for Medical use in Kyrgyzstan, the Department of Drugs Security and Medical Engineering of the Ministry of Health of the Kyrgyz Republic is used for analysis. Results: Analysis showed that the leaders of the pharmaceutical market in Kyrgyzstan the number of registered medicines (M) under the trade names are Medical Drugs (MD) with international generic name: diclofenac, ketorolac, indomethacin. It has been established that there are 99 trade names of NSAIDs of the groups of acetic acid derivatives in the Kyrgyz pharmaceutical market. The largest part of the range consists of diclofenac (M01AB05), represented by 62 trade names MD (62.6%), and ketorolac (M01AB15), represented by 20 trade names MD (20.2%). In the pharmaceutical market of Kyrgyzstan are NSAIDs from the groups of acetic acid derivatives from 15 countries, of which 21.1% of MDs are produced by neighboring countries, and 73.3% – in far countries. Conducted studies have revealed that the structure of the range of NSAIDs groups of acetic acid derivatives is dominated by soft medicinal forms, which making up 37.4%. A comparative analysis of the composition of MD by the number of active substances revealed that 92.9% of NSAIDs of the groups of acetic acid derivatives are monodrugs. Based on the analysis of the price segmentation of NSAIDs of the groups of acetic acid derivatives, most of the drugs are in the low-price segment. Conclusions: A sufficient assortment saturation of the pharmaceutical market of Kyrgyzstan NSAIDs groups of acetic acid derivatives has been revealed. The pharmaceutical market of the Kyrgyz Republic is dominated by monocomponent NSAIDs in the form of soft medicinal forms produced in foreign countries. Only 7 MDs from this group are in the high-price range, making the remaining drugs financially available to consumers. Keywords: NSAIDs, indomethacin, diclofenac, etodolac, ketorolac, aceclophenac.

scholarly journals Research of medicinal products of the nsaid of the pharmaceutical market in Ukraine for the period 2014–2018

2019 ◽  
pp. 41-51
Author(s):  
L. V. Iakovlieva ◽  
A. A. Titova
Keyword(s):  
Generic Drugs ◽  
Low Cost ◽  
Pharmaceutical Market ◽  
Chemical Structures ◽  
Wide Range ◽  
Retail Prices ◽  
Inflammatory Drugs ◽  
Anti Inflammatory ◽  
Trade Names ◽  
Target Characteristics

Nonsteroidal Anti-Inflammatory Drugs (NSAIDs) are groups of different chemical structures of drugs (derivatives of acids) that are widely used in clinical practice. More than three million people in the world take NSAIDs every day. The aim of the study – аnalysis of the range and target characteristics of nonsteroidal anti-inflammatory drugs in the Ukrainian pharmaceutical market during 2014–2018. Nonsteroidal anti-inflammatory drugs, presented on the pharmaceutical market of Ukraine for 2014–2017, were selected as research objects. The research used retail prices, according to the «Pharmstandard» system of the «Morion» company. NSAIDs in Ukraine during 2014–2018 were represented from 302 to 419 TN based on 32 INN. Diclofenac was also represented by the largest number of trade names, due to its distinct efficacy, less toxicity among the most effective drugs and the low cost of domestic generic drugs. Fewer TN than Diclofenac but more than the bulk of NSAIDs in the market were presented by the following INNs – meloxicam, ibuprofen, nimesulide and a combination of glucosamine with chondroitin sulfate. A large selection of NSAIDs has been identified in the pharmaceutical market of Ukraine. Imported Nonsteroidal anti-inflammatory drugs are more represented. These drugs have a wide range of prices that allow you to optimize your treatment costs. The prices of NSAIDs for researched period had increase. The reason can be in conditions of political and socio-economic crisis in the country

scholarly journals The effectiveness of switching from an originator biological agent to its biosimilar, or vice versa, for ankylosing spondylitis in real clinical practice

2020 ◽  
Vol 14 (4) ◽  
pp. 157-160
Author(s):  
K. V. Sakharova ◽  
M. V. Podryadnova ◽  
Sh. F. Erdes
Keyword(s):  
Clinical Practice ◽  
Ankylosing Spondylitis ◽  
Clinical Efficacy ◽  
Standard Therapy ◽  
Biological Agent ◽  
Biological Drugs ◽  
Inflammatory Drugs ◽  
Anti Inflammatory ◽  
Trade Names ◽  
Real Clinical Practice

If standard therapy with nonsteroidal anti-inflammatory drugs is ineffective, biological drugs are usually prescribed for patients with active ankylosing spondylitis. These medicines are purchased in Russia not under their trade names, but under their international non-proprietary ones. This leads to the fact that either originator drugs or their biosimilars are purchased from time to time. For this reason, without a patient' and his/her attending physician's knowledge, the originator drug is switched to its biosimilar, or vice versa. The paper describes two cases of multiple switches from an originator drug to its biosimilars, or vice versa, which are not clinically indicated. The results of analyzing these cases confirm the opinion that biosimilars may have a significantly different clinical efficacy from their originator drugs.

scholarly journals Evaluation of community pharmacists’ roles in screening and communication of risks about non-steroidal anti-inflammatory drugs in Thailand

2018 ◽  
Vol 19 (6) ◽  
pp. 598-604 ◽  
Author(s):  
Pacharaporn Phueanpinit ◽  
Juraporn Pongwecharak ◽  
Janet Krska ◽  
Narumol Jarernsiripornkul
Keyword(s):  
Risk Factors ◽  
Good Practice ◽  
Safety Information ◽  
Community Pharmacists ◽  
Risk Patients ◽  
History Of ◽  
Inflammatory Drugs ◽  
Anti Inflammatory ◽  
Almost All ◽  
Selective Nsaid

AbstractAimThis study aimed to explore community pharmacists’ roles on screening for risk factors, providing safety information-related non-steroidal anti-inflammatory drugs (NSAIDs) to patients.BackgroundNSAIDs are widely dispensed without a prescription from pharmacies in Thailand, while they are frequently reported as causing adverse events.MethodsSelf-administered questionnaires were distributed to all accredited pharmacies in Thailand, inviting the main pharmacist in each pharmacy to participate in this study.FindingsOut of 406 questionnaires distributed, 159 were returned (39.2%). Almost all pharmacists claimed to engage in NSAID dispensing practice, but not all of them provided relevant good practice, such as, screening for risk factors (56.3–95.5%), communication on adverse drug reactions (ADRs) (36.9–63.2%) and ADR management (58.9–79.7%), history of gastrointestinal (GI) problems was frequently mentioned for screening, but many pharmacists did not screen for history of NSAID use (24.7–35.5%), older age (45.2–48.9%), concomitant drug (63.7%), and problems of cardiovascular (24.1%), renal (34.9–43.3%), and liver systems (60.3–61.0%). Male pharmacists were significantly less likely to inform users of non-selective NSAIDs about ADRs [odds ratio (OR) 0.44], while provision of information about selective NSAID ADRs was higher among pharmacy owners (OR 2.28), pharmacies with more pharmacists (OR 3.18), and lower in pharmacies with assistants (OR 0.41). Screening for risk factors, and risk communication about NSAIDs were not generally conducted in Thai accredited community pharmacists, nor were NSAID complications fully communicated. Promoting of community pharmacists’ roles in NSAID dispensing should give priority to improving, especially in high-risk patients for taking NSAIDs.

Non-steroidal Anti-inflammatory Analgesics for Acute Pain Management in Dogs and Cats

1997 ◽  
Vol 10 (03) ◽  
pp. 122-129 ◽  
Author(s):  
Karol A. Mathews
Keyword(s):  
Pain Management ◽  
Gastric Ulceration ◽  
Acute Pain Management ◽  
Post Operative Pain ◽  
Inflammatory Drugs ◽  
Anti Inflammatory ◽  
Trade Names ◽  
To Receive ◽  
Indications For Use ◽  
Better Than

SummaryThe recently developed non-steroidal anti-inflammatory drugs, discussed in this article, have been shown to be efficacious in controlling post-operative pain, used either alone or in combination with opioids, in both cats and dogs. In some instances selected non-steroidal anti-inflammatory analgesics appear to confer superior analgesia to opioids after orthopedic surgery. However, the side-effects of these drugs are an important factor in selecting the appropriate candidate to receive these analgesics. The contra-indications for use of non-steroidal anti-inflammatory drugs should be strictly adhered to. The trade names listed in this article may differ from those used in individual countries. The reader is advised to consult their own pharmacopea for trade names in the individual’s own country.Recently developed, parenteral NSAIAs have been shown to be effective in managing postoperative pain in cats and dogs. In some instances, individual NSAIAs are equal to, and may be better than, opioid agonists in treating moderate to severe post-operative or medical pain. However, due to the concern for renal failure, gastric ulceration with hemorrhage and hemostatic abnormalities with individual NSAIA administration, caution must be used when selecting patients to receive these analgesics. Indications, relative contraindications and absolute contraindications for NSAIA use are discussed. A pain assessment scale (p. 128) with descriptors and suggestions for pain management are also discussed.

Polyphenols from Cymbopogon citratus inhibit iNOS expression and NO production – a promising source of new anti-inflammatory drugs

Planta Medica ◽  
2010 ◽  
Vol 76 (12) ◽  
Author(s):  
V Francisco ◽  
A Figueirinha ◽  
B Neves ◽  
C Garcia-Rodriguez ◽  
M Lopes ◽  
...  
Keyword(s):  
Inos Expression ◽  
No Production ◽  
Cymbopogon Citratus ◽  
Inflammatory Drugs ◽  
Anti Inflammatory ◽  
Promising Source

Heparin and proteoglycans as anti-inflammatory drugs

1996 ◽  
Vol 16 (01) ◽  
pp. 56-59
Author(s):  
D. J. Tyrrell ◽  
C. P. Page
Keyword(s):  
Inflammatory Diseases ◽  
Therapeutic Applications ◽  
Wide Range ◽  
Inflammatory Drugs ◽  
Anti Inflammatory

SummaryEvidence continues to accumulate that the pleiotropic nature of heparin (beyond its anticoagulant potency) includes anti-inflammatory activities at a number of levels. It is clear that drugs exploiting these anti-inflammatory activities of heparin may offer exciting new therapeutic applications to the treatment of a wide range of inflammatory diseases.

Sign in / Sign up

Export Citation Format

Share Document